Symptomatic Relief Policy (SRP) in CAMHS (<18 years) Inpatients on Huntlyburn Ward ONLY

Warning

Objectives

To enable nursing staff to administer selected ‘when required’ medications to patients admitted as inpatients under CAMHS.

The policy is in place to ensure that nursing (and midwifery) staff (given the provisos in No 3 below) can supply appropriate ‘when required’ medications in the interests of patient comfort.  The eight medications included in the CSRP are detailed in the table.

Procedure

  1. A prescriber should prescribe the medications included in the policy by entering on the Medicine Chart ‘CAMHS Symptomatic Relief Policy’ in the As Required Section. The entry should be signed and dated in the normal manner. Or on the mental health medicine charts the prescriber is required to sign the “symptomatic relief policy” box on the as required section of medicines, annotate ‘CAMHS’ on the entry, date it and add any appropriate exclusions.
  1. The prescriber may exclude any of the items which in their judgement would not be appropriate, e.g. “CAMHS Symptomatic Relief Policy except for Paracetamol tablets”.
  1. The nurse or midwife must record administration on the administration part of the Medicine Chart by entering the letter of the medicine and the amount given.
  1. The dose(s) administered must not exceed the maximum stated on the CSRP. If further treatment is required a prescriber must be contacted.
  1. Use of the CSRP must be reviewed weekly by the prescriber and/or clinical pharmacist and appropriate adjustment to the Medicine Chart made.
  1. This policy excludes patients who have a purple “end of life” care drug chart, as they have in place a comprehensive “When Required” medication section and any patients 18 years or older.

Table of Medications Permitted Under Policy and Associated Codes for Kardexes

Code Drug Indication Dose Max Dose allowed Contraindications
A Paracetamol Pain By MOUTH

Child 6–7 years
240–250 mg, every 4–6 hours; maximum 4 doses per day.

Child 8–9 years
360–375 mg, every 4–6 hours; maximum 4 doses per day.

Child 10–11 years
480–500 mg, every 4–6 hours; maximum 4 doses per day.

Child 12–15 years
480–750 mg, every 4–6 hours; maximum 4 doses per day.

Child 16–17 years
0.5–1 g, every 4–6 hours; maximum 4 doses per day.

Available as 120mg/5ml and 250mg/5ml liquids. Tablets, as 500mg, are also available if tolerated, and soluble or effervescent tablets can be ordered from Pharmacy

Maximum 4 doses per day Patients already receiving the maximum dose of paracetamol

Patients on co-codamol, co-dydramol or any combination product which includes paracetamol

allergy to paracetamol

recent overdose of paracetamol

concerns about liver function
B Senna Constipation by mouth using tablets

Child 6-17 years
7.5mg - 15mg once daily, to be adjusted according to response

By mouth using syrup

Child 4–17 years

3.75–15mg once daily, to be adjusted according to response.

Tablets are available as 7.5mg strength and liquid is available as 7.5mg/5ml strength.

15mg in 24 hours

Intestinal obstruction

Recent gastro-intestinal surgery

Acute or chronic gastro-intestinal condition

Medical review if patient has been on anti diarrhoeal medication (also

these should be stopped)

Not to be used in pregnancy

F Peptac Dyspepsia Up to 10ml may be given at any one time 4 doses (40ml) in 24 hours  
G Liquid Paraffin 50%
White Soft Paraffin 50%
Emollient Apply as required No Maximum Allergy to constituents
J Cetirizine Hayfever Child 6-11 years
5mg twice daily

Child 12-17 years
10mg once daily

Available as either 10mg tablets or 1ml/ml liquid


1 dose in 24 hours Not to be used in pregnancy

Not to be used in breastfeeding

Drowsiness

Severe liver impairment

Lactose intolerance

Roles and Responsibilities

Role                        Responsibility

Prescriber                 Annotate Kardex as per policy

Nursing Staff             Administer with Kardex as per policy & document codes on Kardex

Editorial Information

Next review date: 31/05/2027

Author(s): Richardson-Read S.

Version: 1.0

Co-Author(s): Boeing L .

Approved By: ADTC

Reviewer name(s): Barron M.